208.68
price down icon0.65%   -1.37
after-market  After Hours:  208.68 
loading
Penumbra Inc stock is currently priced at $208.68, with a 24-hour trading volume of 343.55K. It has seen a -0.65% decreased in the last 24 hours and a -6.06% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $210.0 pivot point. If it approaches the $207.1 support level, significant changes may occur.

Penumbra Inc Stock (PEN) Financials Data

Penumbra Inc (PEN) Revenue 2024

PEN reported a revenue (TTM) of $1.06 billion for the quarter ending December 31, 2023, a +24.95% rise year-over-year.
loading

Penumbra Inc (PEN) Net Income 2024

PEN net income (TTM) was $90.95 million for the quarter ending December 31, 2023, a +4,643% increase year-over-year.
loading

Penumbra Inc (PEN) Cash Flow 2024

PEN recorded a free cash flow (TTM) of $82.12 million for the quarter ending December 31, 2023, a +209.55% increase year-over-year.
loading

Penumbra Inc (PEN) Earnings per Share 2024

PEN earnings per share (TTM) was $2.31 for the quarter ending December 31, 2023, a +4,083% growth year-over-year.
loading

Penumbra Inc Stock (PEN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Roberts Johanna
EVP, Gen. Counsel & Secretary
Apr 01 '24
Sale
217.07
600
130,242
64,281
Kassing Don W.
Director
Apr 01 '24
Sale
223.18
170
37,941
1,175
Elsesser Adam
CEO and President
Mar 06 '24
Option Exercise
7.75
5,000
38,750
5,000
Bose Arani
Director
Mar 04 '24
Sale
250.20
7,500
1,876,500
164,294
Kassing Don W.
Director
Mar 01 '24
Sale
234.72
778
182,612
1,345
Roberts Johanna
EVP, Gen. Counsel & Secretary
Mar 01 '24
Sale
237.68
600
142,607
62,997
Grewal Harpreet
Director
Jan 03 '24
Sale
240.82
170
40,939
8,980
Sarna Surbhi
Director
Jan 02 '24
Sale
247.68
85
21,053
2,295
Roberts Johanna
EVP, Gen. Counsel & Secretary
Dec 27 '23
Option Exercise
22.04
2,450
53,998
63,597
Roberts Johanna
EVP, Gen. Counsel & Secretary
Dec 01 '23
Sale
226.42
600
135,851
62,251
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
medical_devices PHG
$20.15
price down icon 0.89%
medical_devices STE
$200.24
price up icon 0.62%
$300.14
price down icon 1.63%
medical_devices ZBH
$121.30
price down icon 0.63%
$133.86
price down icon 1.95%
medical_devices EW
$87.24
price down icon 3.12%
Cap:     |  Volume (24h):